Arsanis, Inc., a Waltham, Massachusetts-based clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, closed a $45.5m Series D financing.
The round was led by the Bill & Melinda Gates Foundation with participation from new investors GV (formerly Google Ventures) and Alexandria Venture Investments and existing investors OrbiMed, Polaris Venture Partners, SV Health Investors, NeoMed, EMBL Ventures and the Anna Maria and Stephen Kellen Foundation.
The company intends to use the funds to complete the ongoing Phase 2 study for ASN100 for the prevention of Staphylococcus aureus pneumonia in high-risk mechanically ventilated patients and advance preclinical gram-negative programs, as well as its respiratory syncytial virus program, toward the clinic.
Led by Rene Russo, Pharm.D., BCPS, chief executive officer, Arsanis is a clinical-stage biotechnology company developing targeted monoclonal antibodies (mAbs) for pre-emptive therapy and treatment of serious infectious diseases. The company is building a broad product pipeline addressing the most important infectious diseases. Its lead clinical program, ASN100 is a combination of two human monoclonal antibodies, ASN-1 and ASN-2, that disarms S. aureus without propagating antibiotic resistance by broadly neutralizing the six cytotoxins implicated in the pathogenesis of pneumonia. It is being evaluated in a Phase 2 clinical study for the prevention of Staphylococcus aureus pneumonia in high-risk patients. In addition to its ASN100 program for S. aureus, Arsanis is advancing its pipeline of mAbs targeting serious bacterial and viral infections including multi-drug resistant Escherichia coli and Klebsiella pneumoniae, Streptococcus pneumoniae, and RSV.
The company has European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).